Back

Increasing the class of foundational medication for heart failure is associated with improved prognosis in hospitalized patients with heart failure with reduced or mildly reduced ejection fraction

27 August 2022 (12:15 - 12:45)
Organised by:
Congress Presentation Part of: Chronic heart failure treatment Pharmacotherapy ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Daichi Maeda

Juntendo University Graduate School of Medicine, Tokyo (Japan)

4 More presentations in this session

Presentation thumbnail
Heart failure therapy in new onset heart failure versus chronic heart failure: an analysis of 90,383 patients from the Swedish Heart Failure Registry (SwedeHF)
Ms A. Shahim (Stockholm, SE)
Abstract Slides
Presentation thumbnail
Ultra-fast remote up-titration of heart failure treatment: a safe, efficient and feasible protocol
Doctor M. Massot (Toulouse, FR)
Abstract Slides
Presentation thumbnail
Effects of sodium glucose cotransporter 2 inhibitors on the risk of hyperkalemia in patients on mineralocorticoid receptor antagonist: a systematic review and meta-analysis
Doctor R. Cordovez (Cebu City, PH)
Abstract Slides
Presentation thumbnail
Effect of diuretic down-titration on pulmonary congestion assessed by lung ultrasound when introducing sodium-glucose cotransporter 2 inhibitors
Doctor M. Domingo (Badalona, ES)
Abstract Slides

Access the full session

Session thumbnail
Chronic heart failure treatment

The Event

Event poster

ESC Congress 2022

27 August 2022 12:15 CET
You may be interested in
thumbnail
Congress Session
Guideline-directed medical therapy implementation in special clinical scenarios
thumbnail
Congress Presentation
Audience Q&A
thumbnail
Congress Session
Meet the Experts: summation of the science - treatment of chronic heart failure in 2023

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources